Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
Lusvertikimab (OSE-127)
Pegrizeprument (FR104)
BI 770371
ABBV-230
CLEC-1
Research & Development
Scientific publications
Investors
Press Releases
Letter to Shareholders
Newsletters
Q & A
Financial documents
General Shareholders’ meetings
Regulated information
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Contact
en
fr
C
a
t
é
g
o
r
i
e
:
N
o
n
c
l
a
s
s
é
January 2019
Article 14
January 2019
Article 15
January 2019
Article 1
January 2019
Article 2
January 2019
Article 3
January 2019
Article 4
Précédent
1
2